This SDS packet was issued with item: 078500074

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078830221 078830239 078929355

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078442474 078500066



MATERIAL SAFETY DATA SHEET

Product Id: West Nile Innovator + VEWT 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

Product Code: RM1000199

Product Name: West Nile Innovator + VEWT

- Common Name: West Nile Encephalitis Virus, Equine Encephalomyelitis Virus (Venezuelan, Eastern and Western strains), Equine Influenza Virus (Prague 56 and Kentucky 97 strains), killed virus vaccine and Tetanus Toxoid vaccine
- Supplier: Fort Dodge Animal Health 800 5th Street NW PO Box 518 Fort Dodge, IA 50501

General Information No.: (515) 955-4600 Emergency Telephone No.: (515) 955-6033

Emergency Telephone Number: (800) 424-9300

General Telephone Number: (515) 955-4600

Prepared By: Environmental, Health + Safety

2. COMPOSITION/INFORMATION ON INGREDIENTS					
Components	Weight %	ACGIH TWA:	CAS-No.	Wyeth OEG:	Units for TWAs, STELs, ACGIH, OSHA:
Killed virus None	Unknown	None	NA	Not Established	mg/m3
Adjuvant	Trade secret	None	NA	Not Established	mg/m3
May contain thimerosal, neomycin, formalin, polymyxin B and/or amphotericin B as a preservative		None	Various	Not Established	mg/m3

3. HAZARDS IDENTIFICATION

Inhalation:

Inhalation exposure is unlikely when product is used as directed in a wellventilated space.

Product Name:

West Nile Innovator + VEWT

Page 1 of 6

Obtained by Global Safety Management, Inc. (www.globalsafetynet.com)

Skin Contact:	None known. If product contacts skin, wash thoroughly with soap and water. Seek medical attention if symptoms occur.
Ingestion:	Seek medical attention immediately. Provide physician with MSDS, package insert, and product container.
Eye Contact:	Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Seek medical attention. May cause eye irritation.

4. FIRST AID MEASURES

Eye Contact:	Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Seek medical attention. May cause eye irritation.
Skin Contact:	No known effect. After contact with skin, wash immediately with plenty of water.
Inhalation:	No specific data. If the victim is not breathing, perform mouth-to-mouth resuscitation. Seek medical attention.
Ingestion:	If ingested, seek medical advice immediately and show the container or the label.
Aggravated Conditions:	None known.
Notes to Physician:	For self-inoculation, immediately wash injection site with soap and water. Bleeding, if present, from the puncture wound should be encouraged. Direct treatment at control of symptoms.

5. FIRE FIGHTING MEASURES		
Extinguishing Media and Fire Fighting Instructions:	Aqueous solutions are non-flammable. Use DRY chemicals, CO2, water spray or alcohol foam.	
Special Hazards:	None. Dispose of fire debris and contaminated fire fighting water in accordance with regulations.	

Personal Protective Equipment: No special precautions or equipment.

6. ACCIDENTAL RELEASE MEASURES

Methods For Cleaning Up:	Absorb with an inert material and place in an appropriate waste disposal container.
Personal Precautions:	Put on appropriate personal protective equipment (see Section 8).
Environmental Precautions:	Dike spill area and do not allow product to reach sewage system and surface or ground water.

7. HANDLING AND STORAGE

Handling

Technical Measures/Precautions: No special technical measures required when product is used as directed on label or package insert.

Revision Date: 4/10/2007 Product Name: West Nile Innovator + VEWT

Page 2 of 6

Safe Handling Advice:	No special precautions required. Avoid contact with eyes. After handling, always wash hands thoroughly with soap and water.
Storage	
Technical Measures/Storage Conditions:	Keep only in original container. Keep at temperature not exceeding 7°C. Keep out of the reach of children.
Incompatible Products:	No information available

EXPOSURE CONTROLS/PERSONAL PROTECTION 8.

Engineering Measures:	No special measures required.	
Personal Protective Equipment		
Respiratory Protection:	A respirator is not needed under normal and intended conditions of product use.	
Hand Protection:	Latex gloves	
Skin and Body Protection:	Gloves, Latex. Wear overalls or long sleeved shirt and long trousers.	
Eye Protection:	Safety glasses with side-shields.	
Hygiene Measures:	Avoid contact with skin, eyes and clothing.	

9. PHYSICAL AND CHEMICAL PROPERTIES

Color:	Reddish-white
Odor:	Odorless
pH:	6 - 8
Boiling Point/Range:	Not applicable
Melting Point/Range:	Not determined
Density:	Not determined
Vapor Density:	not determined
Physical State:	Opaque liquid
Vapor Pressure:	not determined
Viscosity	Not applicable
Partition Coefficient:	Not applicable
Solubility:	Easily soluble in cold water, hot water. methanol n-octanol Acetone Diethyl ether
Solubility in Other Solvents:	None known
Flash Point: Explosion limits	Not applicable
- upper	no data available
- lower	no data available
Autoignition Temperature:	Not applicable
Decomposition Temperature:	Not applicable
Dust Explosivity	Not applicable.

10. STABILITY AND REACTIVITY

Revision Date:

Product Name:

4/10/2007 West Nile Innovator + VEWT

Page 3 of 6

Stability:	Stable.	
Conditions to Avoid:	This product is stable.	
Materials to Avoid:	None	
Polymerization:	None known	

Hazardous Decomposition Products: None

11. TOXICOLOGICAL INFORMATION

Acute Toxicity:

LC50/inhalation/rat =	not determined
Principle Routes of Exposure:	None
Eye Contact:	Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Seek medical attention. May cause eye irritation.
Skin Contact:	None known. If product contacts skin, wash thoroughly with soap and water. Seek medical attention if symptoms occur.
Ingestion:	Seek medical attention immediately. Provide physician with MSDS, package insert, and product container.
Inhalation:	No evidence of risk in humans.
Chronic Toxicity:	
Target Organs	None
Specific Effects:	Not determined
Sensitization:	Not known to be a skin sensitizer.
Carcinogenic Effects:	There are no known effects from chronic exposure to this product. No evidence of human carcinogenic effects.
Mutagenic Effects:	Adverse health effects are considered unlikely when the product is administered according to label directions.
Teratogenic Effects:	No evidence of risk in humans. No known human teratogenic effect.
ReproductiveToxicity:	Not considered to be toxic for the reproductive system.
Aggravated Conditions:	None known.

12. ECOLOGICAL INFORMATION

Environmental Fate:	Not evaluated. No known signif	icant effects or c	critical hazards.
Environmental Hazards:	None		
		Revision Date: Product Name:	4/10/2007 West Nile Innovator + VEWT

Page 4 of 6

Ecotoxicity Effects:	This product has no known eco-toxicological effects.	
Aquatic Toxicity:	Not determined.	
Mobility:	No data available	
Bioaccumulation:	Not determined	
Environmental Precautions:	Dike spill area and do not allow product to reach sewage system and surface or ground water.	

13. DISPOSAL CONSIDERATIONS

Waste/Unused Products:

Waste must be disposed of in accordance with federal, state and local environmental control regulations.

Contaminated Packaging:

Not applicable

14. TRANSPORT INFORMATION

DOT (Road/Rail Transport)

UN/ID Number:	Not controlled.
Proper Shipping Name:	Not controlled.
Hazard Class:	Not controlled.
Packing Group:	Not controlled.
DOT Reportable Quantity (Ibs):	Not controlled.
Marine Pollutant:	No
ICAO/IATA (Air Transport):	
UN/ID Number:	Not controlled.
Proper Shipping Name:	Not controlled.
Hazard Class:	Not controlled.
Packing Group:	Not controlled.
IMO/IMDG (Maritime Transport):	
UN/ID Number:	Not controlled.
Hazard Class:	Not controlled.
Packing Group:	Not controlled.
Marine Pollutant:	No

15. REGULATORY INFORMATION

Other Regulations:

Not controlled

16. OTHER INFORMATION

Revision Date: 4/10/2007 Product Name: W

West Nile Innovator + VEWT

Page 5 of 6

Obtained by Global Safety Management, Inc. (www.globalsafetynet.com)

Additional Advice:

Use this product only in accordance with the directions provided on the product label or the package insert.

The information provided in this MSDS is based on current knowledge. However, this does not constitute a warranty by the Company for that information. The product user is responsible for the appropriate and intended handling, use, and disposal of this product in accordance with label or package insert precautions and this information. All materials may present unknown hazards and should be used with caution.
*** End of Safety Data Sheet ***

Revision Date: 4/10/2007 Product Name: W

West Nile Innovator + VEWT

Page 6 of 6



Revision date: 24-Sep-2013

Version: 2.0

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: West Nile Innovator + VEWT

Trade Name: Chemical Family: WEST NILE-INNOVATOR® + VEWT Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Restrictions on Use: Veterinary Vaccine Not for human use

Details of the Supplier of the Safety Data Sheet

Zoetis Inc. 100 Campus Drive, P.O. Box 651 Florham Park, New Jersey 07932 (USA) Rocky Mountain Poison Control Center Phone: 1-866-531-8896 Product Support/Technical Services Phone: 1-800-366-5288

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: VMIPSrecords@zoetis.com Zoetis Belgium S.A. Mercuriusstraat 20 1930 Zaventem Belgium

Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Appearance:

Reddish white liquid

Classification of the Substance or Mixture GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements	
Signal Word:	Not Classified
Hazard Statements:	Not classified in accordance with international standards for workplace safety.
Other Hazards	
Short Term:	In the event of accidental injection, an allergic reaction may occur. If an allergic reaction
	occurs, the worker should be removed to the nearest emergency room and the appropriate
	therapy instituted. This product is an oil-adjuvanted suspension. Oil-adjuvant containing products may cause severe vasospasm following accidental injection. May be harmful if
	swallowed. May cause eye and skin irritation
Australian Hazard Classification (NOHSC):	Non-Hazardous Substance. Non-Dangerous Goods.

Material Name: West Nile Innovator + VEWT Revision date: 24-Sep-2013

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Thimerosal	54-64-8	200-210-4	T+; R26/27/28 R33 N;R50/53	Acute Tox. 2 (H300) STOT RE 2 (H373) Acute Tox. 2 (H330)	##
Polymyxin B	1404-26-8	215-768-4	Xn;R22 Xn;R42/43	Acute Tox. 4 (H302) Skin Sens. 1 (H317) Resp Sens. 1 (H334)	##
Neomycin sulfate	1405-10-3	Not Listed	Not Listed	Not Listed	##
Formaldehyde	50-00-0	200-001-8	T; R23/24/25 C; R34 Carc.Cat.3; R40 R43	Acute Tox. 3 (H301) Skin Corr. 1B (H314) Skin Sens. 1 (H317) Carc. 2 (H351) Acute Tox. 3 (H331)	##

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
EASTERN EQUINE ENCEPHALOMYELITIS	Not Assigned	Not Listed	Not Listed	Not Listed	*
WESTERN EQUINE ENCEPHALOMYELITIS	Not Assigned	Not Listed	Not Listed	Not Listed	*
/enezuelan Equine Enchephalomyelitis	Not Assigned	Not Listed	Not Listed	Not Listed	*
Vest Nile Virus, killed	Not assigned	Not Listed	Not Listed	Not Listed	*
Fetanus toxoid	93384-51-1	297-262-3	Not Listed	Not Listed	*

Additional Information:

Trace * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

	4. FIRST AID MEASURES
Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do no induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Symptoms and Effects of	ffects, Both Acute and Delayed No data available
Exposure: Medical Conditions Aggravated by Exposure:	None known
dication of the Immediate Medi	cal Attention and Special Treatment Needed
Notes to Physician:	Where parenteral oil-adjuvanted vaccine exposure has occurred, the patient should be promptly evaluated for the development of vasospasm and/or compartment syndrome.
	5. FIRE-FIGHTING MEASURES
tinguishing Media:	Extinguish fires with CO2, extinguishing powder, foam, or water.
becial Hazards Arising from the Hazardous Combustion Products:	Substance or Mixture Formation of toxic gases is possible during heating or fire.
Fire / Explosion Hazards:	Fine particles (such as dust and mists) may fuel fires/explosions.
lvice for Fire-Fighters During all fire fighting activiti	es, wear appropriate protective equipment, including self-contained breathing apparatus.
	6. ACCIDENTAL RELEASE MEASURES
	Equipment and Emergency Procedures up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
nvironmental Precautions Place waste in an appropriat	ely labeled, sealed container for disposal. Care should be taken to avoid environmental release.
ethods and Material for Contain Measures for Cleaning / Collecting:	The ment and Cleaning Up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean s area thoroughly.
Additional Consideration f Large Spills:	or Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personne
Earge Opins.	

Precautions for Safe Handling

Material Name: West Nile Innovator + VEWT Revision date: 24-Sep-2013

Page 4 of 11 Version: 2.0

7. HANDLING AND STORAGE

Avoid accidental injection. Use with adequate ventilation. Minimize generating airborne mists and vapors. Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

 Storage Conditions:
 Store as directed by product packaging.

 Storage Temperature:
 2-7°C. Do not freeze.

 Incompatible Materials:
 This material can be denatured or inactivated by a variety of organic solvents, salts or heavy metals.

 Specific end use(s):
 No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

....

Refer to available public information for specific member state Occupational Exposure Limits.

Neomycin sulfate	
Zoetis OEL TWA 8-hr	100µg/m³, Sensitizer
Formaldehyde	
ACGIH Ceiling Threshold Limit:	0.3 ppm
ACGIH - Sensitizer Designation	Sensitizer
Australia STEL	2 ppm
	2.5 mg/m ³
Australia TWA	1 ppm
	1.2 mg/m ³
Austria OEL - MAKs	0.5 ppm
	0.6 mg/m ³
Bulgaria OEL - TWA	1.0 mg/m ³
Czech Republic OEL - TWA	0.5 mg/m ³
Estonia OEL - TWA	0.5 ppm
	0.6 mg/m ³
Finland OEL - TWA	0.3 ppm
	0.37 mg/m ³
France OEL - TWA	0.5 ppm
Germany (DFG) - MAK	0.3 ppm
	0.37 mg/m ³ no irritation should occur during mixed exposure
Greece OEL - TWA	2 ppm
	2.5 mg/m ³
Hungary OEL - TWA	0.6 mg/m ³
Ireland OEL - TWAs	2 ppm
	2.5 mg/m ³
Japan - OELs - Ceilings	0.2 ppm
	0.24 mg/m ³
Latvia OEL - TWA	0.5 mg/m ³
Lithuania OEL - TWA	0.5 ppm
	0.6 mg/m ³
Netherlands OEL - TWA	0.15 mg/m ³
Vietnam O EL - TWAs	0.5 mg/m ³
OSHA - Final PELS - TWAs:	0.75 ppm

8. EXPOSURE CONTR	OLS / PERSONAL PROTECTION
OSHA - Specifically Regulated Chemicals	2 ppm
	0.5 ppm 0.75 ppm
Poland OEL - TWA	0.5 mg/m ³
Romania OEL - TWA	1 ppm 1.20 mg/m ³
Slovakia OEL - TWA	0.3 ppm 0.37 mg/m ³
Slovenia OEL - TWA	0.5 ppm 0.62 mg/m ³
Sweden OEL - TWAs	0.3 ppm 0.37 mg/m ³
Switzerland OEL -TWAs	0.3 ppm 0.37 mg/m ³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Polymyxin B	
Zoetis OEB	OEB 2 - Sensitizer (control exposure to the range of 100ug/m ³ to < 1000ug/m ³ , provide additional precautions to protect from skin contact)
Exposure Controls	
Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep air contamination levels below the exposure limits or within the OEB range listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Opaque liquid	Color:	Reddish white
Odor:	Odorless	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility: Water Solubility: pH: Melting/Freezing Point (°C): Boiling Point (°C): Partition Coefficient: (Method, pH, E No data available Decomposition Temperature (°C):	No data available Soluble 6-8 No data available No data available. indpoint, Value) No data available.		

Page 6 of 11 Version: 2.0

Evaporation Rate (Gram/s):No data availableVapor Pressure (kPa):No data availableVapor Density (g/ml):No data availableRelative Density:No data availableViscosity:No data available

Flammablity:

Autoignition Temperature (Solid) (°C): Flammability (Solids): Flash Point (Liquid) (°C): Upper Explosive Limits (Liquid) (% by Vol.): Lower Explosive Limits (Liquid) (% by Vol.): Polymerization: No data available No data available Non-flammable No data available No data available Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available **Chemical Stability:** Stable under normal conditions of use. **Possibility of Hazardous Reactions Oxidizing Properties:** None Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** This material can be denatured or inactivated by a variety of organic solvents, salts or heavy metals. **Hazardous Decomposition** Thermal decomposition products may include carbon monoxide, carbon dioxide and other toxic Products: vapors.

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects General Information:

Toxicological properties of the formulation have not been investigated. The information included in this section describes the potential hazards of the individual ingredients. The antigens included in this product are non-infectious. All have been prepared from killed or inactivated preparations of microorganisms.

Acute Toxicity: (Species, Route, End Point, Dose)

Thimerosal

Rat Oral LD50 75 mg/kg Mouse Oral LD50 91 mg/kg Rat Subcutaneous LD50 98mg/kg

Polymyxin B

Mouse Oral LD50 790 mg/kg Mouse Para-periosteal LD50 3980ug/kg Rat Subcutaneous LD50 50mg/kg

Formaldehyde

Rat Oral LD50 800 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

11. TOXICOLOGICAL INFORMATION

Thimerosal

Eye Irritation Rabbit Mild

Formaldehyde

Eye IrritationRabbitSevereSkin IrritationRabbitModerate SevereSkin Irritation / SensitizationTh

ere This product contains formaldehyde and merthiolate which are considered to be skin sensitizers.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Formaldehyde

Dog 90 Day(s) Inhalation Not Specified Lungs 90 Day(s) Inhalation Not Specified Rat Lungs 90 Day(s) Monkey Inhalation Not Specified Lungs 9 Day(s) Rat Inhalation 15 ppm LOAEL Respiratory system

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Formaldehyde

Embryo / Fetal DevelopmentMouseOral 185 mg/kg/dayNot teratogenic, Maternal toxicityEmbryo / Fetal DevelopmentRatInhalation 40 ppmNot Teratogenic, Maternal Toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Polymyxin B

In Vitro Negative In Vivo Negative

Formaldehyde

In Vitro Bacterial Mutagenicity (Ames)BacteriaPositiveIn Vitro Chromosome AberrationRodentPositiveIn Vitro Sister Chromatid ExchangeRodentPositiveIn Vivo Chromosome AberrationNot specifiedPositive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Formaldehyde

2 Year(s) Rat Inhalation 6 ppm LOAEL Tumors 2 Year(s) Mouse Inhalation 15 ppm LOAEL Tumors

Carcinogen Status:None of the components present in this material at concentrations equal to or greater than
0.1% are listed by IARC, NTP, OSHA, or ACGIH as a carcinogen.

Formaldehyde

IARC:	Group 1 (Carcinogenic to Humans)
NTP:	Known Human Carcinogen
OSHA:	Listed

12. ECOLOGICAL INFORMATION

Environmental Overview:	The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:Dispose of waste in accordance with all applicable laws and regulations. Member State
specific and Community specific provisions must be considered. Considering the relevant
known environmental and human health hazards of the material, review and implement
appropriate technical and procedural waste water and waste disposal measures to prevent
occupational exposure and environmental release. It is recommended that waste minimization
be practiced. The best available technology should be utilized to prevent environmental
releases. This may include destructive techniques for waste and wastewater. This product
contains trace quantities of mercury and may qualify as a RCRA Hazardous Waste. Status
should be confirmed using the EPA Toxicity Characteristic Leaching Procedure (TCLP).

Formaldehyde RCRA - U Series Wastes

Listed

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Non-controlled

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

15. REGULATORY INFORMATION

EASTERN EQUINE ENCEPHALOMYELITIS	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
WESTERN EQUINE ENCEPHALOMYELITIS	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
Venezuelan Equine Enchephalomyelitis	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
EU EINECS/ELINCS LIST	Not Listed
West Nile Virus, killed	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
Tetanus toxoid	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling	Schedule 4
for Drugs and Poisons:	
EU EINECS/ELINCS List	297-262-3
Thimerosal	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
EU EINECS/ELINCS List	200-210-4
Polymyxin B	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	215-768-4
Neomycin sulfate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	developmental toxicity initial date 10/1/92 internal use
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

F

15. REGULATORY INFORMATION

_		
Forma	aldehyde	
	CERCLA/SARA 313 Emission reporting	0.1 %
	CERCLA/SARA Hazardous Substances	100 lb
	and their Reportable Quantities:	45.4 kg
	CERCLA/SARA - Section 302 Extremely Hazardous TPQs	500 lb
	CERCLA/SARA - Section 302 Extremely Hazardous	100 lb
	Substances EPCRA RQs	
	California Proposition 65	carcinogen initial date 1/1/88 gas
	OSHA - Specifically Regulated Chemicals	2 ppm
		0.5 ppm
		0.75 ppm
	Inventory - United States TSCA - Sect. 8(b)	Present
	Australia (AICS):	Present
	Standard for the Uniform Scheduling	Schedule 2
	for Drugs and Poisons:	Schedule 6
	EU EINECS/ELINCS List	200-001-8

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.2; H300 - Fatal if swallowed Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure Acute toxicity, inhalation-Cat.2; H300 - Fatal if inhaled Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction Sensitization, respiratory-Cat.1; H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage Carcinogenicity-Cat.2; H351 - Suspected of causing cancer Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled

C - Corrosive Carcinogenic: Category 3 N - Dangerous for the environment T+ - Very toxic T - Toxic Xn - Harmful R22 - Harmful if swallowed. R33 - Danger of cumulative effects. R34 - Causes burns.

R40 - Limited evidence of a carcinogenic effect

R43 - May cause sensitization by skin contact.

R26/27/28 - Very toxic by inhalation, in contact with skin and if swallowed.

R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed.

R42/43 - May cause sensitization by inhalation and skin contact.

R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources:

The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Material Name: West Nile Innovator + VEWT Revision date: 24-Sep-2013 Page 11 of 11 Version: 2.0

Reasons for Revision:	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 8 - Exposure Controls / Personal Protection.
Prepared by:	Toxicology and Hazard Communication Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet



Revision date: 24-Sep-2013

Version: 2.0

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: West Nile Innovator + VEWT

Trade Name: Chemical Family: WEST NILE-INNOVATOR® + VEWT Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Restrictions on Use: Veterinary Vaccine Not for human use

Details of the Supplier of the Safety Data Sheet

Zoetis Inc. 100 Campus Drive, P.O. Box 651 Florham Park, New Jersey 07932 (USA) Rocky Mountain Poison Control Center Phone: 1-866-531-8896 Product Support/Technical Services Phone: 1-800-366-5288

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: VMIPSrecords@zoetis.com Zoetis Belgium S.A. Mercuriusstraat 20 1930 Zaventem Belgium

Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Appearance:

Reddish white liquid

Classification of the Substance or Mixture GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements	
Signal Word:	Not Classified
Hazard Statements:	Not classified in accordance with international standards for workplace safety.
Other Hazards Short Term:	In the event of accidental injection, an allergic reaction may occur. If an allergic reaction occurs, the worker should be removed to the nearest emergency room and the appropriate therapy instituted. This product is an oil-adjuvanted suspension. Oil-adjuvant containing products may cause severe vasospasm following accidental injection. May be harmful if swallowed. May cause eve and skin irritation
Australian Hazard Classification (NOHSC):	Non-Hazardous Substance. Non-Dangerous Goods.

Material Name: West Nile Innovator + VEWT Revision date: 24-Sep-2013

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Thimerosal	54-64-8	200-210-4	T+; R26/27/28 R33 N;R50/53	Acute Tox. 2 (H300) STOT RE 2 (H373) Acute Tox. 2 (H330)	##
Polymyxin B	1404-26-8	215-768-4	Xn;R22 Xn;R42/43	Acute Tox. 4 (H302) Skin Sens. 1 (H317) Resp Sens. 1 (H334)	##
Neomycin sulfate	1405-10-3	Not Listed	Not Listed	Not Listed	##
Formaldehyde	50-00-0	200-001-8	T; R23/24/25 C; R34 Carc.Cat.3; R40 R43	Acute Tox. 3 (H301) Skin Corr. 1B (H314) Skin Sens. 1 (H317) Carc. 2 (H351) Acute Tox. 3 (H331)	##

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
EASTERN EQUINE ENCEPHALOMYELITIS	Not Assigned	Not Listed	Not Listed	Not Listed	*
WESTERN EQUINE ENCEPHALOMYELITIS	Not Assigned	Not Listed	Not Listed	Not Listed	*
Venezuelan Equine Enchephalomyelitis	Not Assigned	Not Listed	Not Listed	Not Listed	*
West Nile Virus, killed	Not assigned	Not Listed	Not Listed	Not Listed	*
Tetanus toxoid	93384-51-1	297-262-3	Not Listed	Not Listed	*

Additional Information:

Trace

* Proprietary Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

	4. FIRST AID MEASURES
Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do no induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Nost Important Symptoms and Effe Symptoms and Effects of	No data available
Exposure: Medical Conditions Aggravated by Exposure:	None known
ndication of the Immediate Medical	Attention and Special Treatment Needed
Notes to Physician:	Where parenteral oil-adjuvanted vaccine exposure has occurred, the patient should be promptly evaluated for the development of vasospasm and/or compartment syndrome.
	5. FIRE-FIGHTING MEASURES
extinguishing Media:	Extinguish fires with CO2, extinguishing powder, foam, or water.
Special Hazards Arising from the So Hazardous Combustion Products:	ubstance or Mixture Formation of toxic gases is possible during heating or fire.
Fire / Explosion Hazards:	Fine particles (such as dust and mists) may fuel fires/explosions.
dvice for Fire-Fighters During all fire fighting activities,	wear appropriate protective equipment, including self-contained breathing apparatus.
6.	ACCIDENTAL RELEASE MEASURES
	quipment and Emergency Procedures should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Environmental Precautions Place waste in an appropriately	labeled, sealed container for disposal. Care should be taken to avoid environmental release.
lethods and Material for Containm Measures for Cleaning / Collecting:	ent and Cleaning Up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean sp area thoroughly.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
La go opino.	

Precautions for Safe Handling

Material Name: West Nile Innovator + VEWT Revision date: 24-Sep-2013

Page 4 of 11 Version: 2.0

7. HANDLING AND STORAGE

Avoid accidental injection. Use with adequate ventilation. Minimize generating airborne mists and vapors. Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions:Store as directed by product packaging.Storage Temperature:2-7°C. Do not freeze.Incompatible Materials:This material can be denatured or inactivated by a variety of organic solvents, salts or heavy
metals.Specific end use(s):No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

....

Refer to available public information for specific member state Occupational Exposure Limits.

Neomycin sulfate	
Zoetis OEL TWA 8-hr	100µg/m³, Sensitizer
Formaldehyde	
ACGIH Ceiling Threshold Limit:	0.3 ppm
ACGIH - Sensitizer Designation	Sensitizer
Australia STEL	2 ppm
	2.5 mg/m ³
Australia TWA	1 ppm
	1.2 mg/m ³
Austria OEL - MAKs	0.5 ppm
	0.6 mg/m ³
Bulgaria OEL - TWA	1.0 mg/m ³
Czech Republic OEL - TWA	0.5 mg/m ³
Estonia OEL - TWA	0.5 ppm
	0.6 mg/m ³
Finland OEL - TWA	0.3 ppm
	0.37 mg/m ³
France OEL - TWA	0.5 ppm
Germany (DFG) - MAK	0.3 ppm
	0.37 mg/m ³ no irritation should occur during mixed exposure
Greece OEL - TWA	2 ppm
	2.5 mg/m ³
Hungary OEL - TWA	0.6 mg/m ³
Ireland OEL - TWAs	2 ppm
	2.5 mg/m ³
Japan - OELs - Ceilings	0.2 ppm
	0.24 mg/m ³
Latvia OEL - TWA	0.5 mg/m ³
Lithuania OEL - TWA	0.5 ppm
	0.6 mg/m ³
Netherlands OEL - TWA	0.15 mg/m ³
Vietnam O EL - TWAs	0.5 mg/m ³
OSHA - Final PELS - TWAs:	0.75 ppm

Reddish white No data available.

Mixture

8. EXPOSURE CONTROLS / PERSONAL PROTECTION		
OSHA - Specifically Regulated Chemicals	2 ppm 0.5 ppm 0.75 ppm	
Poland OEL - TWA	0.5 mg/m ³	
Romania OEL - TWA	1 ppm 1.20 mg/m ³	
Slovakia OEL - TWA	0.3 ppm 0.37 mg/m ³	
Slovenia OEL - TWA	0.5 ppm 0.62 mg/m ³	
Sweden OEL - TWAs	0.3 ppm 0.37 mg/m ³	
Switzerland OEL -TWAs	0.3 ppm 0.37 mg/m ³	

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Polymyxin B	
Zoetis OEB	OEB 2 - Sensitizer (control exposure to the range of 100ug/m ³ to < 1000ug/m ³ , provide additional precautions to protect from skin contact)
Exposure Controls	
Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep air contamination levels below the exposure limits or within the OEB range listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Odor:	Opaque liquid Odorless	Color: Odor Threshold:
Molecular Formula:	Mixture	Molecular Weight:
Solvent Solubility:	No data available	
Water Solubility:	Soluble	
pH:	6-8	
Melting/Freezing Point (°C):	No data available	
Boiling Point (°C):	No data available.	
Partition Coefficient: (Method, pH, E	Endpoint, Value)	
No data available	• • •	
Decomposition Temperature (°C):	No data available.	

Page 6 of 11 Version: 2.0

Evaporation Rate (Gram/s):No data availableVapor Pressure (kPa):No data availableVapor Density (g/ml):No data availableRelative Density:No data availableViscosity:No data available

Flammablity:

Autoignition Temperature (Solid) (°C): Flammability (Solids): Flash Point (Liquid) (°C): Upper Explosive Limits (Liquid) (% by Vol.): Lower Explosive Limits (Liquid) (% by Vol.): Polymerization: No data available No data available Non-flammable No data available No data available Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available **Chemical Stability:** Stable under normal conditions of use. **Possibility of Hazardous Reactions Oxidizing Properties:** None Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** This material can be denatured or inactivated by a variety of organic solvents, salts or heavy metals. **Hazardous Decomposition** Thermal decomposition products may include carbon monoxide, carbon dioxide and other toxic Products: vapors.

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects General Information:

Toxicological properties of the formulation have not been investigated. The information included in this section describes the potential hazards of the individual ingredients. The antigens included in this product are non-infectious. All have been prepared from killed or inactivated preparations of microorganisms.

Acute Toxicity: (Species, Route, End Point, Dose)

Thimerosal

Rat Oral LD50 75 mg/kg Mouse Oral LD50 91 mg/kg Rat Subcutaneous LD50 98mg/kg

Polymyxin B

Mouse Oral LD50 790 mg/kg Mouse Para-periosteal LD50 3980ug/kg Rat Subcutaneous LD50 50mg/kg

Formaldehyde

Rat Oral LD50 800 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

11. TOXICOLOGICAL INFORMATION

Thimerosal

Eye Irritation Rabbit Mild

Formaldehyde

Eye IrritationRabbitSevereSkin IrritationRabbitModerate SevereSkin Irritation / SensitizationTh

ere This product contains formaldehyde and merthiolate which are considered to be skin sensitizers.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Formaldehyde

Dog 90 Day(s) Inhalation Not Specified Lungs 90 Day(s) Inhalation Not Specified Rat Lungs 90 Day(s) Monkey Inhalation Not Specified Lungs 9 Day(s) Rat Inhalation 15 ppm LOAEL Respiratory system

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Formaldehyde

Embryo / Fetal DevelopmentMouseOral 185 mg/kg/dayNot teratogenic, Maternal toxicityEmbryo / Fetal DevelopmentRatInhalation 40 ppmNot Teratogenic, Maternal Toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Polymyxin B

In Vitro Negative In Vivo Negative

Formaldehyde

In Vitro Bacterial Mutagenicity (Ames)BacteriaPositiveIn Vitro Chromosome AberrationRodentPositiveIn Vitro Sister Chromatid ExchangeRodentPositiveIn Vivo Chromosome AberrationNot specifiedPositive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Formaldehyde

2 Year(s) Rat Inhalation 6 ppm LOAEL Tumors 2 Year(s) Mouse Inhalation 15 ppm LOAEL Tumors

Carcinogen Status: None of the components present in this material at concentrations equal to or greater than 0.1% are listed by IARC, NTP, OSHA, or ACGIH as a carcinogen.

Formaldehyde

IARC:	Group 1 (Carcinogenic to Humans)
NTP:	Known Human Carcinogen
OSHA:	Listed

12. ECOLOGICAL INFORMATION

Environmental Overview:	The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:Dispose of waste in accordance with all applicable laws and regulations. Member State
specific and Community specific provisions must be considered. Considering the relevant
known environmental and human health hazards of the material, review and implement
appropriate technical and procedural waste water and waste disposal measures to prevent
occupational exposure and environmental release. It is recommended that waste minimization
be practiced. The best available technology should be utilized to prevent environmental
releases. This may include destructive techniques for waste and wastewater. This product
contains trace quantities of mercury and may qualify as a RCRA Hazardous Waste. Status
should be confirmed using the EPA Toxicity Characteristic Leaching Procedure (TCLP).

Formaldehyde RCRA - U Series Wastes

Listed

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Non-controlled

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

15. REGULATORY INFORMATION

EASTERN EQUINE ENCEPHALOMYELITIS	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
WESTERN EQUINE ENCEPHALOMYELITIS	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
Venezuelan Equine Enchephalomyelitis	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
	Not Elstou
West Nile Virus, killed	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
Tetanus toxoid	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling	Schedule 4
for Drugs and Poisons: EU EINECS/ELINCS List	297-262-3
EU EINECS/ELINCS LIST	291-202-3
Thimerosal	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
EU EINECS/ELINCS List	200-210-4
Polymyxin B	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	215-768-4
Neomycin sulfate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	developmental toxicity initial date 10/1/92 internal use
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

F

15. REGULATORY INFORMATION

Form	aldehyde	
	CERCLA/SARA 313 Emission reporting	0.1 %
	CERCLA/SARA Hazardous Substances	100 lb
	and their Reportable Quantities:	45.4 kg
	CERCLA/SARA - Section 302 Extremely Hazardous TPQs	500 lb
	CERCLA/SARA - Section 302 Extremely Hazardous	100 lb
	Substances EPCRA RQs	
	California Proposition 65	carcinogen initial date 1/1/88 gas
	OSHA - Specifically Regulated Chemicals	2 ppm
		0.5 ppm
		0.75 ppm
	Inventory - United States TSCA - Sect. 8(b)	Present
	Australia (AICS):	Present
	Standard for the Uniform Scheduling	Schedule 2
	for Drugs and Poisons:	Schedule 6
	EU EINECS/ELINCS List	200-001-8

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.2; H300 - Fatal if swallowed Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure Acute toxicity, inhalation-Cat.2; H300 - Fatal if inhaled Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction Sensitization, respiratory-Cat.1; H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage Carcinogenicity-Cat.2; H351 - Suspected of causing cancer Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled

C - Corrosive Carcinogenic: Category 3 N - Dangerous for the environment T+ - Very toxic T - Toxic Xn - Harmful R22 - Harmful if swallowed. R33 - Danger of cumulative effects. R34 - Causes burns.

R40 - Limited evidence of a carcinogenic effect

R43 - May cause sensitization by skin contact.

R26/27/28 - Very toxic by inhalation, in contact with skin and if swallowed.

R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed.

R42/43 - May cause sensitization by inhalation and skin contact.

R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources:

The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Material Name: West Nile Innovator + VEWT Revision date: 24-Sep-2013 Page 11 of 11 Version: 2.0

Reasons for Revision:	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 8 - Exposure Controls / Personal Protection.
Prepared by:	Toxicology and Hazard Communication Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet